​

Protagonist Therapeutics (PTGX) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChart

PTGX Stock Forecast

Protagonist Therapeutics (PTGX) stock forecast, based on 22 Wall Street analysts, predicts a 12-month average price target of $90.67, with a high of $112.00 and a low of $72.00. This represents a 20.49% increase from the last price of $75.25.

$20 $39 $58 $77 $96 $115 High: $112 Avg: $90.67 Low: $72 Last Closed Price: $75.25

PTGX Stock Rating

Protagonist Therapeutics stock's rating consensus is Buy, based on 22 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 20 Buy (90.91%), 2 Hold (9.09%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 22 0 2 20 Strong Sell Sell Hold Buy Strong Buy

PTGX Price Target Upside V Benchmarks

TypeNameUpside
StockProtagonist Therapeutics20.49%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts349
Avg Price Target$91.33$86.50$76.33
Last Closing Price$75.25$75.25$75.25
Upside/Downside21.37%14.95%1.44%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Oct, 25481--13
Sep, 25371--11
Aug, 25371--11
Jul, 25371--11
Jun, 25451--10
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Oct 28, 2025Srikripa DevarakondaTruist Financial$88.00$76.6814.76%16.94%
Oct 13, 2025Johnson Rice$112.00$87.0028.74%48.84%
Oct 07, 2025Johnson Rice$74.00$65.4713.03%-1.66%
Sep 16, 2025Barclays$72.00$58.5922.89%-4.32%
Mar 11, 2025Wedbush$70.00$59.7617.14%-6.98%
Mar 03, 2025BTIG$73.00$38.5089.61%-2.99%
Dec 05, 2024Etzer DaroutBMO Capital$62.00$41.6848.75%-17.61%
Nov 22, 2024Srikripa DevarakondaTruist Financial$60.00$46.4629.14%-20.27%
Sep 12, 2024Douglas TsaoH.C. Wainwright$50.00$45.0810.91%-33.55%
Jun 17, 2024Douglas TsaoH.C. Wainwright$38.00$32.8615.64%-49.50%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Oct 17, 2025CitigroupBuyBuyhold
Oct 13, 2025BMO CapitalOutperformOutperformhold
Sep 16, 2025BarclaysOverweightinitialise
Aug 07, 2025CitigroupOutperformOutperformhold
Jun 17, 2025CitigroupBuyinitialise
Mar 11, 2025WedbushOutperformOutperformhold
Mar 11, 2025BMO CapitalOutperformOutperformhold
Mar 11, 2025H.C. WainwrightBuyBuyhold
Dec 05, 2024BMO CapitalOutperforminitialise
Oct 14, 2024Cowen & Co.BuyBuyhold

Financial Forecast

EPS Forecast

$-5 $-3 $-1 $1 $3 $5 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-1.92$-2.65$-2.52$-1.39$4.47----
Avg Forecast$-1.94$-2.71$-2.57$-1.62$2.37$-1.30$-1.16$-1.40$0.48
High Forecast$-1.37$-1.92$-1.61$-1.16$3.24$-0.15$1.99$0.71$0.99
Low Forecast$-3.24$-4.54$-4.10$-2.09$1.71$-2.27$-2.71$-3.11$0.06
Surprise %-1.03%-2.21%-1.95%-14.20%88.61%----

Revenue Forecast

$0 $100M $200M $300M $400M $500M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$28.63M$27.36M$26.58M$60.00M-----
Avg Forecast$25.69M$23.20M$29.85M$60.00M$313.30M$97.97M$135.83M$123.87M$262.81M
High Forecast$39.01M$35.22M$43.48M$108.70M$376.48M$177.49M$139.83M$224.40M$476.11M
Low Forecast$19.93M$17.99M$21.25M$19.90M$266.93M$32.50M$131.82M$41.09M$87.17M
Surprise %11.43%17.93%-10.95%------

Net Income Forecast

$-200M $-100M $0 $100M $200M $300M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-66.15M$-122.63M$-123.41M$-78.95M$275.19M----
Avg Forecast$-109.89M$-122.29M$-137.72M$-78.95M$170.85M$-89.38M$-74.54M$-69.47M$27.36M
High Forecast$-77.83M$-97.83M$-110.18M$-63.16M$183.88M$-8.53M$112.84M$40.54M$56.23M
Low Forecast$-183.94M$-146.75M$-165.27M$-94.75M$97.25M$-128.95M$-153.72M$-176.41M$3.59M
Surprise %-39.81%0.27%-10.39%-61.07%----

PTGX Forecast FAQ

Is Protagonist Therapeutics stock a buy?

Protagonist Therapeutics stock has a consensus rating of Buy, based on 22 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 20 Buy, 2 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Protagonist Therapeutics is a favorable investment for most analysts.

What is Protagonist Therapeutics's price target?

Protagonist Therapeutics's price target, set by 22 Wall Street analysts, averages $90.67 over the next 12 months. The price target range spans from $72 at the low end to $112 at the high end, suggesting a potential 20.49% change from the previous closing price of $75.25.

How does Protagonist Therapeutics stock forecast compare to its benchmarks?

Protagonist Therapeutics's stock forecast shows a 20.49% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Protagonist Therapeutics over the past three months?

  • October 2025: 30.77% Strong Buy, 61.54% Buy, 7.69% Hold, 0% Sell, 0% Strong Sell.
  • September 2025: 27.27% Strong Buy, 63.64% Buy, 9.09% Hold, 0% Sell, 0% Strong Sell.
  • August 2025: 27.27% Strong Buy, 63.64% Buy, 9.09% Hold, 0% Sell, 0% Strong Sell.

What is Protagonist Therapeutics’s EPS forecast?

Protagonist Therapeutics's average annual EPS forecast for its fiscal year ending in December 2025 is $-1.3, marking a -129.08% decrease from the reported $4.47 in 2024. Estimates for the following years are $-1.16 in 2026, $-1.4 in 2027, and $0.48 in 2028.

What is Protagonist Therapeutics’s revenue forecast?

Protagonist Therapeutics's average annual revenue forecast for its fiscal year ending in December 2025 is $97.97M, reflecting a 0% decrease from the reported $0 in 2024. The forecast for 2026 is $135.83M, followed by $123.87M for 2027, and $262.81M for 2028.

What is Protagonist Therapeutics’s net income forecast?

Protagonist Therapeutics's net income forecast for the fiscal year ending in December 2025 stands at $-89.382M, representing a -132.48% decrease from the reported $275.19M in 2024. Projections indicate $-74.543M in 2026, $-69.472M in 2027, and $27.36M in 2028.